Bristol Myers Squibb Explained

Bristol-Myers Squibb Company
Trade Name:Bristol Myers Squibb
Former Name:Bristol-Myers Company (1887–1989)
Type:Public
Industry:Pharmaceuticals
Predecessors:Squibb Corporation (1858–1989)
Area Served:Worldwide
Revenue: (2023)
Operating Income: (2023)
Net Income: (2023)
Assets: (2023)
Equity: (2023)
Num Employees:34,100 (2023)
Footnotes:[1]

The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey,[2] BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.

BMS's primary research and development (R&D) sites are located in Lawrence, New Jersey (formerly Squibb, near Princeton), Summit, New Jersey, formerly HQ of Celgene, New Brunswick, New Jersey, Redwood City, California, and Seville in Spain, with other sites in Devens and Cambridge, Massachusetts, Braine-l'Alleud, Belgium, Tokyo, Japan, Hyderabad; Bangalore India[3] and Wirral, United Kingdom.[4] [5] BMS previously had an R&D site in Wallingford, Connecticut (formerly Bristol-Myers).[6]

History

Squibb

The Squibb corporation was founded in 1858 by Edward Robinson Squibb in Brooklyn, New York.[7] [8] Squibb was known as an advocate of quality control and high purity standards early within the pharmaceutical industry.[9] He went on to self-publish an alternative to the U.S. Pharmacopeia titled Squibb's Ephemeris of Materia Medica, after failing to convince the American Medical Association to incorporate higher purity standards.[10]

Materia Medica, Squibb products, and Edward Squibb's opinion on the fundamentals of pharmacy are found in many medical papers of the late 1800s.[11] [12] [13] [14] The American Journal of Pharmacy published more than one hundred papers of Squibb's research surrounding the industry.[15]

The sons of Edward Squibb sold the company to Lowell M. Palmer and Theodore Weicker in 1905, who incorporated the company. Around this time, the Squibb logo was developed, which represented the company's products of "uniformity, purity, efficacy, and reliability based on research."[16]

Squibb Corporation served as a major supplier of medical goods to the Union Army during the American Civil War, providing portable medical kits containing morphine, surgical anesthetics, and quinine for the treatment of malaria (which was endemic in most of the Eastern United States at that time).[17] [18]

In 1944, Squibb opened the world's largest penicillin plant in New Brunswick, New Jersey.[19]

Bristol-Myers

In 1887, Hamilton College graduates William McLaren Bristol and John Ripley Myers purchased the Clinton Pharmaceutical company of Clinton, New York.[20] In May 1898, they decided to rename it Bristol, Myers and Company. Following Myers' death in 1899, Bristol changed the name to the Bristol-Myers Corporation.

During the 1890s, the company introduced its first nationally recognized product Sal Hepatica, a laxative mineral salt, followed by Ipana toothpaste in 1901.[21] [22] Other divisions were Clairol (hair colors and haircare) and Drackett (household products such as Windex and Drano).[23]

In 1943, Bristol-Myers acquired Cheplin Biological Laboratories, a producer of acidophilus milk in East Syracuse, New York,[24] and converted the plant to produce penicillin for the World War II Allied forces.[25] After the war, the company renamed the plant Bristol Laboratories in 1945 and entered the civilian antibiotics market, where it faced competition from Squibb.

Penicillin production at the East Syracuse plant ended in 2005, when it became less expensive to produce overseas.[26] [27] As of 2010, the facility was used for the manufacturing process development and production of other biologic medicines for clinical trials and commercial use.[28] [29]

Merger

In 1989, Bristol-Myers and Squibb merged and became Bristol-Myers Squibb.[30]

In 1999, then-U.S. President Bill Clinton awarded Bristol-Myers Squibb the National Medal of Technology, the nation's highest recognition for technological achievement, "for extending, and enhancing human life through innovative pharmaceutical research and development and for redefining the science of clinical study through groundbreaking and hugely complex clinical trials that are recognized models in the industry."[31]

2000 to 2010

In 2002, the company was involved in a lawsuit of illegally maintaining a monopoly on Taxol, its cancer treatment, and it was again sued for the antitrust lawsuit five years later, which cost the company $125 million for settlement.[32]

Also in 2002, Bristol-Myers Squibb was involved in an accounting scandal that resulted in a significant restatement of revenues from 1999 to 2001.[33] The restatement was the result of an improper booking of sales related to "channel stuffing" as the practice of offering excess inventory to customers to create higher sales numbers. The company has since settled with the United States Department of Justice and Securities and Exchange Commission, agreeing to pay $150 million, while neither admitting nor denying guilt.[34]

On October 24, 2002, Bristol-Myers Squibb Co. restated earnings downward for parts of 2000 and 2001, while revising 2002 earnings upward because of its massive inventory backlog imbroglio that spurred two government investigations.[35] On March 15, 2004, Bristol-Myers Squibb Co. adjusted upward its fourth-quarter and full-year 2003 results after reversing an earlier decision about how to deal with accounting errors made in prior years.[36]

As part of a deferred prosecution agreement, the company was placed under the oversight of a monitor appointed by the U.S. attorney in New Jersey. In addition, the former head of the Pharma group, Richard Lane, and the ex-CFO, Fred Schiff, were indicted for federal securities violations.[37]

In July 2006, an investigation of the company was made public, and the FBI raided the company's corporate offices.[38] The investigation centered on the distribution of Plavix and charges of collusion.[39] On September 12, 2006, the monitor, former Federal Judge Frederick B. Lacey, urged the company to remove then-CEO Peter Dolan over the Plavix dispute. Later that day, BMS announced that Dolan would indeed step down.[40]

The deferred prosecution agreement expired in June 2007 and the Department of Justice did not take any further legal action against the company for matters covered by the DPA. Under CEO Jim Cornelius, who was CEO following Dolan until May 2010, all executives involved in the "channel-stuffing" and generic competition scandals have since left the company.

In 2009, the company began a major restructuring focusing on the pharmaceutical business and biologic products, along with productivity initiatives and cost-cutting and streamlining business operations through a multiyear program of on-going layoffs. This was part of a business strategy launched in 2007 to transform the company from a large, diversified pharmaceutical company to a specialty biopharma company, which also included the closure of half of their manufacturing facilities.[41] As another cost-cutting measure, Bristol-Myers Squibb also reduced health-care subsidies for retirees and planned to freeze their pension plan at the end of 2009.[42] [43]

BMS is a Fortune 500 Company (#114 in 2010 list). Newsweek's 2009 Green Ranking recognized Bristol-Myers Squibb as eighth among 500 of the largest United States corporations. Also, BMS was included in the 2009 Dow Jones Sustainability North America Index of leading sustainability-driven companies.

Lamberto Andreotti was named CEO in 2010; he had previously served as "president and COO responsible for all pharmaceutical operations worldwide."[44]

2010 onward

In 2010, Lou Schmukler joined Bristol-Myers Squibb as the president of global product development and design.[45] Schmukler led the team that completed the company's strategic transformation to a specialty biopharmaceutical company that had begun in 2007. As of 2011, the company had a dozen manufacturing facilities and six product development sites.

Citing major developments and a market capitalization of US$87 billion and stock appreciation of 61.4%, Bristol-Myers Squibb was ranked as the best drug company of 2013 by Forbes magazine.[46]

In December 2014, the company received FDA approval for the use of the PD-1 inhibitor nivolumab (Opdivo) in treating patients whose skin cancer cannot be removed or have not responded to previous drug therapies.[47] In February 2015, the company initiated a research partnership with Rigel Pharmaceuticals which could generate more than $339 million. In March, the company obtained an exclusive opportunity to both licence and commercialise PROSTVAC, Bavarian Nordic's phase III prostate-specific antigen targeting cancer immunotherapy. Bavarian Nordic would receive an upfront payment of $60 million and incremental payments up to $230 million, if the overall survival of test patients exceeds that seen in Phase II tests. Bavarian could also receive milestone payments of between $110 million and $495 million, dependent on regulatory authorization, and these payments have the potential to total up to $975 million.[48]

In May 2015, Dr. Giovanni Caforio became CEO of the company;[49] Caforio was formerly the company's COO and succeeded Andreotti upon his retirement. Andreotti subsequently succeeded James Cornelius as executive chairman upon his retirement.

In late February 2017, The Wall Street Journal and Fortune, among others, reported that activist investor Carl Icahn had taken a stake in the company, signaling a potential future takeover[50] [51] from the likes of Gilead Sciences.[52]

In April 2018, the company reported net income of $1.5 billion, or 91 cents per share, for the first quarter of the year, thanks to the increased sales of their cancer drug Opdivo.[53]

Corporate acquisitions and divestments as Bristol Myers Squibb

In August 2009, during a major restructuring activity, BMS acquired the biotechnology firm Medarex as part of the company's "String of Pearls" strategy of alliances, partnerships, and acquisitions.[54] [55] In November 2009, Bristol Myers Squibb announced that it was "splitting off" Mead Johnson Nutrition by offering BMY shareholders the opportunity to exchange their stock for shares in Mead Johnson.[56] According to Bristol Myers Squibb, this move was expected to further sharpen the company's focus on biopharmaceuticals.

In October 2010, the company acquired ZymoGenetics, securing an existing product, as well as pipeline assets in hepatitis C, cancer, and other therapeutic areas.

Bristol Myers Squibb agreed to pay around $2.5 billion in cash to buy Inhibitex Inc. in attempt to compete with Gilead/Pharmasset to produce hepatitis C drugs. The settlement will be finished in 2 months for its Inhibitex's shareholders acceptance of 126% premium price of its price over the previous 20 trading days ended on January 6.[57] On June 29, BMS extended its portfolio of diabetes treatments when it agreed to buy Amylin Pharmaceuticals for around in cash and pay to Eli Lilly to cover Amylin's debt and its outstanding collaboration-related obligations.[58] AstraZeneca, which already collaborated on several diabetes treatments with BMS, agreed to pay US$3.4 billion in cash for the right to continue development of Amylin's products. Two years later, the company divested Amylin to AstraZeneca.

In April 2014, BMS announced its acquisition of iPierian for up to $725 million.[59]

In February 2015, the company acquired Flexus Biosciences for $1.25 billion. As part of this deal, BMS will gain full rights to Flexus' lead small molecule IDO1-inhibitor, F001287.[60] In November, the company acquired the cardiovascular disease drug developer Cardioxyl for up to $2.075 billion. The deal strengthens the BMS' critical pipelines with the phase II candidate for acute decompensated heart failure, CXL-1427.[61]

In March 2016, the company announced it would acquire Padlock Therapeutics for up to $600 million.[62] In early July, the company announced it would acquire Cormorant Pharmaceuticals for $520 million, boosting BMS' oncology offering through Cormorants monoclonal antibody targeted against interleukin-8.[63]

In August 2017 the company acquired IFM Therapeutics for $300 million upfront, with contingency payments of $1.01 billion due on certain milestones – allowing BMS to better compete against Merck & Co's cancer rival treatment, Keytruda.[64]

In early January 2019, the company announced it would acquire Celgene (NASDAQ:CELG) for $74 billion ($95 billion including debt[65]), in a deal that would become the largest pharmaceutical-company acquisition ever.[66] The Celgene acquisition aimed to be a refresher to the company's pipeline, helping to overcome from declining sales of Opdivo relative to competitor Keytruda. Under the terms of the deal, Celgene shareholders would receive one BMS share as well as $50 in cash for each Celgene share held, valuing Celgene at $102.43 a share; representing a 54% premium to the previous days closing price.[66] Investor opposition to this acquisition, leading into an April 12 shareholder vote, appeared when BMS's second-largest investor, Wellington Management, voiced its opposition, followed by investor Starboard Value.[67] In April 2019 BMS announced that 75% of its shareholders voted to approve the pending merger with Celgene. Transaction to close in the third quarter of 2019, subject to regulatory approvals.[68] Newly issued BMS shares and CVRs will commence trading on the New York Stock Exchange, with the CVRs trading under the symbol 'BMYRT'.[69]

The strategic divestment of the company's consumer health business, UPSA, to Taisho completed in 2019.[70] UPSA focused product delivery on France and the rest of Europe. As early as 2005, the company had divested individual consumer products, and its US- and Canada-focused consumer products business.

In August, the Amgen announced it would acquire the Otezla drug programme from Celgene for $13.4 billion, as part of Celgene and BMS's merger deal.[71] [72]

In February 2020, BMS and partner Biomotiv launched a new company called Anteros Pharmaceuticals, which focuses on creating inflammation and fibrosis medicines.[73] In August, the business announced it would acquire Forbius and its TGF-beta 1 & TGF-beta 3 inhibitors.[74] In October, BMS announced it would acquire cardiology company MyoKardia for $13.1 billion ($225 per share) gaining control of mavacamten, a cardiovascular drug for obstructive hypertrophic cardiomyopathy (HCM), and the development of two key treatments: danicamtiv (MYK-491) and MYK-224.[75]

In June 2022, BMS announced it would acquire Turning Point Therapeutics Inc for $4.1 billion in cash ($76 per share, a 122.5% premium to its last closing price), helping to boost its complement of cancer drugs, specifically repotrectinib.[76] That same month, the company announced it would be investing $180m in French AI company Owkin, to design potentially more precise and efficient clinical trials. The collaboration will initially focus on cardiovascular diseases, and has the potential to extend into projects in other therapeutic areas.[77]

In August 2023, Bristol Myers Squibb partnered with Cellares for the robotic production of CAR-T treatments of which it has two approved.[78] In September 2023, BMS announced it would pay Zenas BioPharma $50m upfront for a strategic license and collaboration to develop and commercialise obexelimab,[79] a novel, bi-functional antibody for autoimmune diseases.

In October 2023, BMS agreed to acquire Mirati Therapeutics, an American biotechnology company that develops targeted therapies for the treatment of cancer, in an all-cash deal worth $4.8 billion, and an additional $1 billion in milestone payment.[80] The acquisition was completed in January 2024.[81]

In December 2023, BMS signed an agreement for the acquisition of Karuna Therapeutics for an equity value totaling $14 billion.[82] The acquisition included Karuna's lead asset, KarXT, an investigational muscarinic antipsychotic combination of Xanomeline and Trospium.[83] In November 2023, the FDA accepted Karuna Therapeutics' NDA for KarXT, for the treatment of schizophrenia in adults.[84] The acquisition of Karuna Therapeutics was completed in March 2024.[85]

The company entered into an agreement to purchase RayzeBio, for approximately $4.1 billion, in December 2023.[86]

List of mergers and acquisitions

The following is an illustration of the company's major mergers and acquisitions and historical predecessors:

Finances

For the fiscal year 2018,Bristol Myers Squibb reported earnings of US$1.007 billion, with an annual revenue of US$20.776 billion, an increase of 6.9% over the previous fiscal cycle. Bristol-Myers Squibb's shares traded at over $55 per share, and its market capitalization was valued at over US$81.6 billion in October 2018.[87] In 2018, 85% of the company's revenues came from just five products.[88] In 2018, Bristol-Myers Squibb spent 36% of its total revenue on R&D expenses.[89] Bristol-Myers Squibb ranked 145th on the Fortune 500 list of the largest United States corporations by revenue in 2018.[90]

YearRevenue
in bil. US$		Net income
in bil. US$		Total assets
in bil. US$		Price per share
in US$		Employees
200518.603.0028.1414.60
200616.201.5925.5815.24
200715.622.1725.9318.98
200817.725.2529.4914.95
200918.8110.6031.0015.90
201019.483.0931.0819.76
201121.243.7032.9723.41
201217.621.9635.9028.04
201316.392.5638.6038.3928,000
201415.882.0033.7547.0325,000
201516.561.5731.7559.6325,000
201619.434.4533.7159.7325,000
201720.781.0033.5555.8823,700
201822.564.9234.9951.9823,300
201926.153.44129.4452.2330,000
202042.52−9.02118.4862.0330,250
202146.396.99109.3162.3532,200
202246.166.3396.8271.9534,300

Carbon footprint

Bristol Myers Squibb reported Total CO2e emissions (Direct + Indirect) for the twelve months ending 31 December 2020 at 278 Kt (-6 /-2.1% y-o-y).[91] The company aims to become net neutral carbon by 2040.[91]

Pharmaceuticals

The following is a list of key pharmaceutical products:[92] Cardiovascular diseases

Diabetes mellitus

Infectious diseases, including HIV infection and associated conditions

Inflammatory disorders

Oncology

Psychiatry

Rheumatic disorders

Transplant rejection

Out of production

Divested brands

(Former Bristol-Myers brands, now divested)

Products under development

The following is a selective list of investigational products under development, as of 2023:[98]

Public-private engagement

Bristol-Myers Squibb engages with the public and private sectors through the promotion of research and development, academic funding, event sponsorship, philanthropy, and political lobbying.

Academia and education

Conferences and events

Healthcare

Media

Medical societies

Political lobbying

Professional associations

Research and development

Scandals

Bristol-Myers Squibb, Johns Hopkins University and the Rockefeller Foundation are currently the subject of a $1 billion lawsuit from Guatemala for "roles in a 1940s U.S. government experiment that infected hundreds of Guatemalans with syphilis".[146] A previous suit against the United States government was dismissed in 2011 for the Guatemala syphilis experiments when a judge determined that the U.S. government could not be held liable for actions committed outside of the U.S.[147]

See also

Notes and References

  1. Web site: Bristol Myers Squibb 2023 Annual Report (Form 10-K) . 13 February 2024 . SEC.gov . . 15 February 2024 . 15 February 2024 . https://web.archive.org/web/20240215230450/https://www.sec.gov/ix?doc=/Archives/edgar/data/14272/000001427224000044/bmy-20231231.htm . live .
  2. Web site: Bristol-Myers Squibb Company . Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 (Form 8-K) . SEC.gov . July 27, 2023 . . August 2, 2023 . 2 August 2023 . https://web.archive.org/web/20230802135524/https://www.sec.gov/ix?doc=/Archives/edgar/data/14272/000001427223000150/bmy-20230727.htm . live .
  3. News: Bristol Myers Squibb to invest Rs 800 crore to set up facility in Hyderabad for drug development, IT. The Economic Times. 23 February 2023. 5 December 2023. 5 December 2023. https://web.archive.org/web/20231205045859/https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bristol-myers-squibb-to-invest-rs-800-cr-to-set-up-facility-in-hyderabad-for-drug-development-it/articleshow/98170745.cms. live.
  4. Bristol-Myers Squibb and Biocon's Syngene open new R&D Facility at Biocon Park . May 16, 2012 . dead . https://web.archive.org/web/20120929024338/http://www.bmsi.co.in/bbrc.aspx?section=2. 29 September 2012. dmy-all.
  5. Web site: Worldwide Research and Development Facilities – Bristol Myers Squibb. www.bms.com. 7 June 2020. 7 June 2020. https://web.archive.org/web/20200607002847/https://www.bms.com/about-us/our-company/worldwide-facilities/our-research-facilities.html. live.
  6. Web site: Bristol-Myers Squibb to lay off 149 as Wallingford, Connecticut, site nears closure . 17 July 2018 . Fiercepharma.com . 3 February 2019 . 4 February 2019 . https://web.archive.org/web/20190204014332/https://www.fiercepharma.com/pharma/bristol-myers-squibb-to-lay-off-149-as-wallingford-site-nears-closure . live .
  7. News: Gray. Christopher. Still in Fashion, a Century Later. 2012-08-30. The New York Times. 2020-03-20. en-US. 0362-4331. 20 March 2020. https://web.archive.org/web/20200320213513/https://www.nytimes.com/2012/09/02/realestate/brooklyn-heights-streetscapes-still-in-fashion-a-century-later.html. live.
  8. Book: Kumar, B.. Mega Mergers and Acquisitions: Case Studies from Key Industries. 2012-11-14. Springer. 978-1-137-00590-8. en. 15 October 2020. 14 April 2021. https://web.archive.org/web/20210414044838/https://books.google.com/books?id=0lAjalmgNBUC&q=squibb+corporation+%221858%22&pg=PA54. live.
  9. Book: The National Druggist. 1905. en. 15 October 2020. 14 April 2021. https://web.archive.org/web/20210414044936/https://books.google.com/books?id=nNgtGmY7iYIC&q=Squibb+was+known+as+an+advocate+of+quality+control+and+high+purity+standards&pg=PA192. live.
  10. Web site: E. R. Squibb American chemist. Encyclopedia Britannica. en. 2020-03-20. 20 March 2020. https://web.archive.org/web/20200320213512/https://www.britannica.com/biography/E-R-Squibb. live.
  11. Inverse Type of Temperature in Typhoid Fever, with a Report of Two Cases — Temperature Peculiarities in Epidemics, with a Report of Seven Cases in One Family . Boston Medical and Surgical Journal . January 8, 1885 . Hollopeter . W.C. . 112 . 28–32 . 10.1056/NEJM188308301090903 . 2014-11-25 . "The writer noticed (in December, 1882) the important fact that when common or Japan camphor and crystallized carbolic acid are mixed together and subjected to heat, a colorless liquid would be the result. The only reference he finds so far with regard to this reaction occurs in the very excellent and valuable scientific publication of Dr. E. R. Squibb, " Ephemeris of Materia Medica", etc., on page 673, vol. ii., No. 5, where a brief allusion appears under the appellation of Compound Alum Powder. Dr. F. R. Squibb, however, in a letter to the writer states that he has " several times before heard of this reaction between phenol and camphor." . 19 October 2015 . https://web.archive.org/web/20151019134348/http://www.nejm.org/doi/full/10.1056/NEJM188710271171706 . live .
  12. Edward Robinson Squibb (1819–1900): Advocate of Product Standards . Journal of the American Pharmacists Association . 2003 . Worthen . Dennis . 46 . 6 . 754–758 . 10.1331/1544-3191.46.6.754.Worthen . 17176693 . 2014-11-25 . https://web.archive.org/web/20140418052223/http://japha.org/article.aspx?articleid=1042039 . 18 April 2014 . dead . dmy-all .
  13. Blake. J.B.. 1899. Administration of Ether at the Boston City Hospital. Boston Med Surg J. 141. 13. 312–314. 10.1056/NEJM189909281411303. "Until within six months Squibb's other has been exclusively used at the Boston City Hospital. Recently .MeliiHTéift's ether has been tried, ¡uni has given fair satisfaction ; Squibb's is still preferred by most of the house officers.". 5 July 2019. 27 July 2020. https://web.archive.org/web/20200727043210/https://zenodo.org/record/1916260. live.
  14. Brown. W.S.. 1885. Forty Year's Experience in Midwifery. Boston Medical and Surgical Journal. 112. 11. 241. 10.1056/nejm188503121121101. "One reason why ergot has fallen into disrepute is the poor quality of many specimens offered for sale. Dr. Squibb's aqueous extract rarely disappoints me.". 5 July 2019. 27 July 2020. https://web.archive.org/web/20200727043103/https://zenodo.org/record/1429884. live.
  15. Book: Capace, Nancy. Encyclopedia of Delaware. 2001-01-01. Somerset Publishers, Inc.. 978-0-403-09612-1. en. 15 October 2020. 14 April 2021. https://web.archive.org/web/20210414044849/https://books.google.com/books?id=u9StYwbI_F8C&q=U.S.+Pharmacopeia+Squibb%27s+Ephemeris+of+Materia+Medica&pg=PA227. live.
  16. Web site: Claire. 2013-08-27. A history of Bristol-Myers Squibb. 2021-08-01. pharmaphorum.com. en-GB. 22 September 2020. https://web.archive.org/web/20200922110355/https://pharmaphorum.com/views-and-analysis/a-history-of-bristol-myers-squibb/. live.
  17. Book: Smith . Medicines for the Union Army: the United States Army laboratories during the Civil War. registration . Pharmaceutical Products Press. 2001. 9780789009470. Accessed 2014-11-25.
  18. Book: Navy Medicine. 2005. Naval Medical Command. en. 15 October 2020. 14 April 2021. https://web.archive.org/web/20210414021917/https://books.google.com/books?id=ueAJxIW6gu0C&q=Bristol-Myers+Squibb+union+army&pg=RA3-PA24. live.
  19. Book: Rosenbloom, Bert. Marketing Channels. 2012-07-25. Cengage Learning. 978-1-133-70757-8. de. 15 October 2020. 14 April 2021. https://web.archive.org/web/20210414044926/https://books.google.com/books?id=6WMJAAAAQBAJ&q=1944&pg=PA609. live.
  20. Book: Cox, Jim. Sold on Radio: Advertisers in the Golden Age of Broadcasting. 2008-09-18. McFarland. 978-0-7864-5176-0. en. 15 October 2020. 14 April 2021. https://web.archive.org/web/20210414022015/https://books.google.com/books?id=RwVkMMLqMdkC&q=In+1887%2C+Hamilton+College+graduates+William+McLaren+Bristol+and+John+Ripley+Myers+purchased+the+Clinton+Pharmaceutical+company+of+Clinton%2C+New+York&pg=PA95. live.
  21. Bert Rosenbloom, Marketing Channels, Bristol-Myers Squibb, 2011, page 609
  22. Web site: Ipana toothpaste tasted success in early 1900s. 2017-04-20. Loveland Reporter-Herald. en-US. 2020-03-26. 19 October 2021. https://web.archive.org/web/20211019181909/https://www.reporterherald.com/2017/04/20/ipana-toothpaste-tasted-success-in-early-1900s/. live.
  23. News: Salpukas. Agis. BUSINESS PEOPLE; 3 Executive Changes Set by Bristol-Myers. 1984-08-16. The New York Times. 2020-03-26. en-US. 0362-4331. 26 March 2020. https://web.archive.org/web/20200326150851/https://www.nytimes.com/1984/08/16/business/business-people-3-executive-changes-set-by-bristol-myers.html. live.
  24. Book: Botti, Timothy J.. Envy of the World: A History of the U.S. Economy & Big Business. 2006. Algora Publishing. 978-0-87586-432-7. en. 15 October 2020. 14 April 2021. https://web.archive.org/web/20210414045008/https://books.google.com/books?id=4UPo0V1qovwC&q=Squibb+world%27s+largest+penicillin+plant+for+army&pg=PA250. live.
  25. Web site: 2013-09-13. Bristol-Myers Squibb marks completion of East Syracuse plant's transformation. 2020-07-09. syracuse. en. 11 July 2020. https://web.archive.org/web/20200711065151/https://www.syracuse.com/news/2013/09/bristol-myers_squibb_marks_completion_of_east_syracuse_plants_transformation.html. live.
  26. Web site: Bristol-Myers Squibb: Big Pharma's small wonder. Fortune. en. 2019-12-10. 10 December 2019. https://web.archive.org/web/20191210192058/https://fortune.com/2014/06/02/fortune-500-bristol-myers/. live.
  27. News: Harris. Gardiner. Drug Making's Move Abroad Stirs Concerns. 2009-01-19. The New York Times. 2020-03-26. en-US. 0362-4331. 26 March 2020. https://web.archive.org/web/20200326152244/https://www.nytimes.com/2009/01/20/health/policy/20drug.html. live.
  28. Web site: At Bristol-Myers Squibb plant in East Syracuse, old buildings will make way for new drugs. 2010-06-30. syracuse. en. 2020-04-28. 27 July 2020. https://web.archive.org/web/20200727052549/https://www.syracuse.com/news/2010/06/at_bristol-myeres_squibb_plant.html. live.
  29. Web site: Bristol Myers Squibb East Syracuse Pharmaceutical Manufacturing Facility – Pharmaceutical Technology. www.pharmaceutical-technology.com. 2020-04-28. 27 July 2020. https://web.archive.org/web/20200727052503/https://www.pharmaceutical-technology.com/projects/bristolmyerseastsyra/. live.
  30. Web site: Bristol-Myers, Squibb Agree to Merge : $12-Billion Stock Swap Would Form 2nd-Largest Drug Firm. 1989-07-28. Los Angeles Times. en-US. 2020-03-26. 26 March 2020. https://web.archive.org/web/20200326151348/https://www.latimes.com/archives/la-xpm-1989-07-28-fi-295-story.html. live.
  31. Web site: NSTMF. NSTMF. 2020-03-26. 26 March 2020. https://web.archive.org/web/20200326151350/https://www.nationalmedals.org/laureates/bristol-myers-squibb-company. live.
  32. News: Bristol hit with antitrust suit . June 4, 2002 . Jul 10, 2013 . CNN . 17 August 2020 . https://web.archive.org/web/20200817125051/https://money.cnn.com/2002/06/04/news/companies/bristol/ . live .
  33. Book: Chopra, Prem. Masters of the Game. 2009. Brook of Life. 978-0-9786321-3-7. en. 15 October 2020. 14 April 2021. https://web.archive.org/web/20210414044839/https://books.google.com/books?id=Np3htQTKG10C&q=2002%2C+Bristol-Myers+Squibb+was+involved+in+an+accounting+scandal+that+resulted+in+a+significant+restatement+of+revenues+from+1999+to+2001&pg=PA327. live.
  34. Bristol-Myers Squibb Company : Lit. Rel. No. 18822 . US Securities and Exchange Commission . May 9, 2015 . August 6, 2004 . Bristol-Myers inflated its results primarily by: (1) stuffing its distribution channels with excess inventory near the end of every quarter in amounts sufficient to meet sales and earnings targets set by officers ("channel-stuffing") . 21 August 2017 . https://web.archive.org/web/20170821063813/https://www.sec.gov/litigation/litreleases/lr18822.htm . live .
  35. Web site: Bristol-Myers to restate earnings as third quarter profits plunge. https://web.archive.org/web/20131105214250/http://www.highbeam.com/doc/1P1-68980061.html . dead . 2013-11-05 .
  36. Web site: Bristol-Myers restates results upward due to accounting errors. https://web.archive.org/web/20150924182701/http://www.highbeam.com/doc/1P1-92165333.html . dead . 2015-09-24 .
  37. News: Saul. Stephanie. 2005-06-15. 2 Former Bristol-Myers Executives Charged With Fraud. en-US. The New York Times. 2020-07-09. 0362-4331. 11 July 2020. https://web.archive.org/web/20200711104240/https://www.nytimes.com/2005/06/15/business/2-former-bristolmyers-executives-charged-with-fraud.html. live.
  38. Web site: Former Bristol-Myers Squibb Senior Executive Pleads Guilty for Role in Dishonest Dealings with the Federal Government. 2020-07-09. FBI. en-us. 19 October 2021. https://web.archive.org/web/20211019181936/https://archives.fbi.gov/archives/washingtondc/press-releases/2009/wfo040609.htm. live.
  39. http://www.busrep.co.za/index.php?fSectionId=565&fArticleId=3367635 Business Report
  40. https://money.cnn.com/2006/09/12/news/companies/bristol/index.htm?postversion=2006091217 CNN.com
  41. News: From Big to Specialty—The Operational Transformation of Bristol-Myers Squibb. Wright. Rob. October 2018. Life Science Leader. 17 October 2018. VertMarkets. 10. Erie, Pennsylvania. 10.
  42. Web site: Bristol-Myers Squibb Announces Pension Risk Transfer PLANSPONSOR. www.plansponsor.com. 2020-04-28. 27 July 2020. https://web.archive.org/web/20200727035012/https://www.plansponsor.com/bristol-meyers-squibb-announces-pension-risk-transfer/. live.
  43. Web site: Bristol-Myers Squibb Closes US Retirement Plan Chief Investment Officer. www.ai-cio.com. 2020-04-28. 27 July 2020. https://web.archive.org/web/20200727041250/https://www.ai-cio.com/news/bristol-myers-squibb-closes-us-retirement-plan/. live.
  44. News: BMS CEO Andreotti to Retire; COO named as Successor. Staff. 15 February 2015. Genetic Engineering & Biotechnology News. paper. 6. 35. 4.
  45. Web site: A Primer On Biopharma Manufacturing From Bristol-Myers Squibb's Lou Schmukler. 2020-07-09. www.lifescienceleader.com. 9 July 2020. https://web.archive.org/web/20200709231446/https://www.lifescienceleader.com/doc/a-primer-on-biopharma-manufacturing-from-bristol-myers-squibb-s-lou-schmukler-0001. live.
  46. News: Grading Pharma in 2013 . Forbes . December 31, 2013 . Matthew . Herper . 25 August 2017 . 27 October 2017 . https://web.archive.org/web/20171027035723/https://www.forbes.com/sites/matthewherper/2013/12/31/grading-pharma-in-2013-16-drug-companies-ranked/ . live .
  47. News: Bristol-Myers Drug Wins U.S. Approval to Treat Advanced Melanoma. Anna Edney. Bloomberg. 22 December 2014. 5 March 2017. 31 December 2014. https://web.archive.org/web/20141231234835/http://www.bloomberg.com/news/2014-12-22/bristol-myers-drug-wins-u-s-approval-to-treat-advanced-melanoma.html. live.
  48. Web site: Bavarian Nordic Could Tally up to $975 Million in Prostate Cancer Deal with BMS – GEN News Highlights – GEN. GEN. 4 March 2015. 5 March 2015. 6 March 2015. https://web.archive.org/web/20150306131553/http://genengnews.com/gen-news-highlights/bavarian-nordic-could-tally-up-to-975m-in-prostate-cancer-deal-with-bms/81250993/. live.
  49. Web site: Johnson. Linda A.. New CEO Takes Over Evolving Drugmaker Bristol-Myers Squibb. ABC News. 6 May 2015. 7 May 2015. https://web.archive.org/web/20150507193842/http://abcnews.go.com/Business/wireStory/ceo-takes-drugmaker-bristol-myers-squibb-30816845. live.
  50. Web site: Bristol-Myers Squibb Shares Just Spiked on Reports of a Carl Icahn Stake. Fortune. 23 May 2017. 5 August 2017. https://web.archive.org/web/20170805221623/http://fortune.com/2017/02/21/carl-icahn-bristol-myers-squibb/. live.
  51. Web site: Carl Icahn Takes Stake in Bristol-Myers Squibb. David. Benoit. Jonathan D.. Rockoff. 22 February 2017. 23 May 2017. The Wall Street Journal. 22 May 2017. https://web.archive.org/web/20170522150438/https://www.wsj.com/articles/carl-icahn-takes-stake-in-bristol-myers-squibb-1487710151. live.
  52. Web site: Making (good) deals is hard to do, Gilead CEO says, but he's working on it – FiercePharma. fiercepharma.com. 23 February 2017 . 23 May 2017. 10 June 2017. https://web.archive.org/web/20170610151034/http://www.fiercepharma.com/m-a/gilead-s-m-a-intentions-include-oncology-inflammation-ceo. live.
  53. Web site: Bristol-Myers' cancer drug Opdivo fuels growth, but revenue falls short. LaVito. Angelica. 2018-04-26. CNBC. en. 2019-12-11. 11 December 2019. https://web.archive.org/web/20191211153534/https://www.cnbc.com/2018/04/26/bristol-myers-squibb-q1-earnings-2018.html. live.
  54. https://finance.yahoo.com/news/BristolMyers-Squibb-to-bw-571310065.html?x=0&.v=1{{Dead link|date=February 2019 |bot=InternetArchiveBot |fix-attempted=yes }}
  55. Web site: Bristol-Myers to Buy Medarex For $2.4 Billion . July 23, 2009 . 5 December 2020 . 14 April 2021 . https://web.archive.org/web/20210414014334/https://dealbook.nytimes.com/2009/07/23/bristol-myers-to-buy-medarex-for-24-billion/ . live .
  56. Web site: Woelfel. Joseph. Bristol-Myers to Split Off Mead Johnson. 2020-07-09. TheStreet. 16 November 2009 . en-us. 10 July 2020. https://web.archive.org/web/20200710015552/https://www.thestreet.com/investing/stocks/bristol-myers-to-split-off-mead-johnson-10626920. live.
  57. Web site: Bristol Buys Inhibitex for $2.5 Billion to Compete in Hepatitis. January 8, 2012.
  58. News: Bristol-Myers to buy Amylin for about US$5.3 billion. Gershberg. Michele. 30 June 2012. Reuters. 5 July 2021. 9 August 2020. https://web.archive.org/web/20200809103249/https://uk.reuters.com/article/uk-amylin-bristolmyerssquibb-idUKBRE85T01U20120630. live.
  59. News: Bristol-Myers buy Inhibitex. Bristol-Myers Squibb. 29 November 2021. 13 December 2015. https://web.archive.org/web/20151213024325/http://news.bms.com/press-release/partnering-news/bristol-myers-squibb-acquires-ipierian-inc. live.
  60. Web site: GEN – News Highlights:BMS Deals Add to its Immuno-Oncology Portfolio. GEN. 23 February 2015. 24 February 2015. 24 February 2015. https://web.archive.org/web/20150224015838/http://www.genengnews.com/gen-news-highlights/bms-deals-add-to-its-immuno-oncology-portfolio/81250955/. live.
  61. Web site: BMS to Buy Cardioxyl for Up to $2.075B. GEN. 2 November 2015. 2 November 2015. 4 March 2016. https://web.archive.org/web/20160304073238/http://www.genengnews.com/gen-news-highlights/bms-to-buy-cardioxyl-for-up-to-2-075b/81251924/. live.
  62. Web site: BMS to Acquire Padlock Therapeutics for Up to $600M. GEN. 23 March 2016. 23 March 2016. 6 September 2017. https://web.archive.org/web/20170906140046/http://www.genengnews.com/gen-news-highlights/bms-to-acquire-padlock-therapeutics-for-up-to-600m/81252509. live.
  63. . August 2016. BMS Snags Cormorant Pharmaceuticals for Up to $520M (online title: BMS Acquires Cormorant Pharmaceuticals for Up to $520M). News: Industry Watch (online: GEN News Highlights). Genetic Engineering & Biotechnology News. 36. 14. 10. 5 July 2016. 10 July 2017. https://web.archive.org/web/20170710110426/http://www.genengnews.com/gen-news-highlights/bms-acquires-cormorant-pharmaceuticals-for-up-to-520m/81252909. live.
  64. News: 3 August 2017 . Bristol-Myers to buy IFM Therapeutics to strengthen cancer pipeline . live . https://web.archive.org/web/20170805221900/http://uk.reuters.com/article/us-ifm-therapeutics-m-a-bristol-myers-idUKKBN1AJ2Z1 . 5 August 2017 . 5 August 2017 . Reuters.
  65. News: Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal. Reuters. 4 January 2019. www.reuters.com. 19 October 2021. 28 April 2021. https://web.archive.org/web/20210428211323/https://www.reuters.com/article/uk-celgene-m-a-bristol-myers-idUKKCN1OY1CA. live.
  66. Web site: Bristol Myers Squibb To Buy Celgene In $74 Billion Cancer-Drug Bet . Rebecca . Spalding . Cynthia . Koons . January 3, 2019 . www.bloomberg.com . 3 January 2019 . 3 January 2019 . https://web.archive.org/web/20190103232910/https://www.bloomberg.com/news/articles/2019-01-03/bristol-myers-squibb-to-buy-celgene-in-74-billion-pharma-deal . live .
  67. News: Starboard joins opposition to Bristol-Myers' $74 billion Celgene deal. Herbst-Bayliss. Svea. 28 February 2019. 3 March 2019. Reuters. Erman. Michael. Starboard reported on Thursday that it now owns 4.4 million shares, or 0.3 percent of Bristol's outstanding shares, while Wellington owns an 8 percent stake.. 28 February 2019. https://web.archive.org/web/20190228174727/https://www.reuters.com/article/us-celgene-m-a-bristol-myers-wellington/celgene-slumps-as-bristol-myers-shareholder-resists-merger-idUSKCN1QH1K7. live.
  68. https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-shareholders-approve-celgene-acquisition Bristol-Myers Squibb Shareholders Approve Celgene Acquisition
  69. Web site: Bristol-Myers Squibb completes acquisition of Celgene. 2019-11-22. European Pharmaceutical Review. en. 2019-12-11. 11 December 2019. https://web.archive.org/web/20191211153540/https://www.europeanpharmaceuticalreview.com/news/106288/bristol-myers-squibb-completes-acquisition-of-celgene/. live.
  70. News: Bristol-Myers Squibb completes divestment of consumer health business, UPSA to Taisho Pharma. 2 July 2019. Pharmabiz.com. 4 July 2019. Saffron Media. India. Churnalism. 27 July 2020. https://web.archive.org/web/20200727050244/http://pharmabiz.com/ArticleDetails.aspx?aid=116689&sid=2. live.
  71. Web site: Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits. BioSpace. 19 October 2021. 19 October 2021. https://web.archive.org/web/20211019181905/https://www.biospace.com/article/amgen-to-acquire-otezla-for-13-4-billion-in-cash-or-approximately-11-2-billion-net-of-anticipated-future-cash-tax-benefits/. live.
  72. News: Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion. Reuters. 26 August 2019. www.reuters.com. 19 October 2021. 30 April 2021. https://web.archive.org/web/20210430080227/https://www.reuters.com/article/us-bristol-myers-divestiture-amgen-idUKKCN1VG102. live.
  73. Web site: Bristol-Myers launches biotech targeting fibrosis, inflammation. BioPharma Dive. en-US. 2020-03-03. 3 March 2020. https://web.archive.org/web/20200303084944/https://www.biopharmadive.com/news/bristol-myers-biomotive-launch-anteros-biotech/571650/. live.
  74. Web site: Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio. BioSpace. 19 October 2021. 19 October 2021. https://web.archive.org/web/20211019181905/https://www.biospace.com/article/bristol-myers-squibb-enters-agreement-to-acquire-forbius-adding-lead-tgf-beta-asset-to-portfolio/. live.
  75. Web site: BMS Strengthens Cardiovascular Business with $13.1 Billion MyoKardia Buyout . Biospace . 2020-10-05 . 2020-11-18 . 11 October 2020 . https://web.archive.org/web/20201011064621/https://www.biospace.com/article/bristol-myers-squibb-buys-myokardia-for-13-1-billion/ . live .
  76. News: Bristol Myers boosts cancer drug portfolio with $4.1 billion Turning Point deal . Reuters . 3 June 2022 . Mishra . Manas . Khandekar . Amruta . 4 June 2022 . 4 June 2022 . https://web.archive.org/web/20220604205144/https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-buy-turning-point-41-bln-2022-06-03/ . live .
  77. Web site: Bristol Myers pays $80M to AI firm Owkin as part of cardiovascular trial accord . Fiercebiotech . 22 March 2024 . 22 March 2024 . https://web.archive.org/web/20240322122934/https://www.fiercebiotech.com/cro/bristol-myers-pays-80m-ai-firm-owkin-part-cardiovascular-trial-accord . live .
  78. Web site: Dunleavy . Kevin . 2023-08-29 . Bristol Myers Squibb partners with Cellares for robotic production of pipeline CAR-T drug . 2023-09-27 . Fierce Pharma . 27 September 2023 . https://web.archive.org/web/20230927065229/https://www.fiercepharma.com/manufacturing/bristol-myers-partners-cellares-robotic-manufacture-pipeline-car-t . live .
  79. Web site: 2023-09-06 . BMS pays Zenas $50m upfront for regional rights to autoimmune disease antibody . 2023-09-15 . PMLive . en . 25 September 2023 . https://web.archive.org/web/20230925085346/https://www.pmlive.com/pharma_news/bms_pays_zenas_$50m_upfront_for_regional_rights_to_autoimmune_disease_antibody_1498294 . live .
  80. News: Condie . Stuart . 8 October 2023 . Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion . The Wall Street Journal . 8 October 2023 . 8 October 2023 . https://web.archive.org/web/20231008231816/https://www.wsj.com/health/pharma/bristol-myers-squibb-to-acquire-mirati-therapeutics-in-deal-worth-up-to-5-8-billion-7d83106 . live .
  81. News: Bristol Myers Squibb concludes Mirati acquisition for $5.8bn . 24 January 2024 . Pharmaceutical Technology . Verdict Media . 28 January 2024 . 28 January 2024 . https://web.archive.org/web/20240128014149/https://www.pharmaceutical-technology.com/news/bristol-myers-squibb-mirati-acquisition/ . live .
  82. Web site: Priyan . Vishnu . 2023-12-26 . BMS agrees to acquire Karuna Therapeutics for $14bn . 2024-01-27 . Pharmaceutical Technology . en-US . 27 January 2024 . https://web.archive.org/web/20240127194949/https://www.pharmaceutical-technology.com/news/bms-to-acquire-karuna/ . live .
  83. Web site: Priyan . Vishnu . 2023-12-26 . BMS agrees to acquire Karuna Therapeutics for $14bn . 2024-01-27 . Pharmaceutical Technology . en-US . 27 January 2024 . https://web.archive.org/web/20240127194949/https://www.pharmaceutical-technology.com/news/bms-to-acquire-karuna/ . live .
  84. Web site: FDA accepts KarXT new drug application for treating schizophrenia . 2024-01-27 . www.healio.com . en . 27 January 2024 . https://web.archive.org/web/20240127200703/https://www.healio.com/news/psychiatry/20231129/fda-accepts-karxt-new-drug-application-for-treating-schizophrenia . live .
  85. Web site: 2024-03-18 . Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio . 2024-03-19 . Yahoo Finance . en-US . 19 March 2024 . https://web.archive.org/web/20240319082008/https://finance.yahoo.com/news/bristol-myers-squibb-completes-acquisition-124400163.html . live .
  86. News: Lauerman . John . Bristol Myers Adds to Buying Spree with Radiological Drugmaker . 26 December 2023 . Bloomberg.com . 26 December 2023 . en.
  87. Web site: Bristol-Myers Squibb Revenue 2006–2018 BMY. macrotrends.net. 2018-10-31. 1 November 2018. https://web.archive.org/web/20181101015725/https://www.macrotrends.net/stocks/charts/BMY/bristol-myers-squibb/revenue. live.
  88. Web site: Bristol-Myers Squibb: Diversity and scale in biopharma. June 2019. DHL. 2019-12-11. 11 December 2019. https://web.archive.org/web/20191211153538/https://www.logistics.dhl/global-en/home/about-us/delivered-magazine/articles/2019/issue-3-2019/bristol-myers-squibb-diversity-scale-biopharma.html. live.
  89. Web site: What Percent Does Bristol-Myers Squibb Spend On R&D, 30%, 40%, Or 50%?. 2019-11-28. Forbes. en. 2019-12-11. 11 December 2019. https://web.archive.org/web/20191211153534/https://www.forbes.com/sites/greatspeculations/2019/11/28/what-percent-does-bristol-myers-squibb-spend-on-rd-30-40-or-50/. live.
  90. Web site: Bristol-Myers Squibb. Fortune. en-US. 2018-11-20. 21 November 2018. https://web.archive.org/web/20181121021955/http://fortune.com/fortune500/bristol-myers-squibb/. live.
  91. Web site: Bristol Myers Squibb's Sustainability Report for 2020Q4 . https://web.archive.org/web/20211010102301/https://www.bms.com/assets/bms/us/en-us/pdf/BMY-2020-ESG-Report.pdf . October 10, 2021 . Alt URL
  92. Web site: Selected Products of Bristol-Myers Squibb. © 2015 Bristol-Myers Squibb Company. 30 May 2015. 4 May 2017. https://web.archive.org/web/20170504023659/https://www.bms.com/patient-and-caregivers/our-medicines.html. live.
  93. Johnson DB, Peng C, Sosman JA . Nivolumab in melanoma: latest evidence and clinical potential . Ther Adv Med Oncol . 7 . 2 . 97–106 . 2015 . 25755682 . 4346215 . 10.1177/1758834014567469 .
  94. Web site: Generic Taxol Availability. drugs.com. 23 January 2018. 30 April 2016. https://web.archive.org/web/20160430104706/http://www.drugs.com/availability/generic-taxol.html. live.
  95. News: Excedrin brand for sale. 12 January 2005. CNN Money. Reuters. News > Fortune 500. 3 August 2020. 16 April 2021. https://web.archive.org/web/20210416115658/https://money.cnn.com/2005/01/12/news/fortune500/bristol/index.htm. live.
  96. Bristol-Myers Squibb to Divest Three Consumer Brands. 21 September 1998. Bristol-Myers Squibb Company. PRNewswire. 4 March 2016. https://web.archive.org/web/20160304115627/https://www.prnewswire.com/news-releases/bristol-myers-squibb-to-divest-three-consumer-brands-76664287.html.
  97. Bristol-Myers Squibb Plans To Divest U.S. And Canadian Consumer Medicines Business. 12 January 2005. Bristol-Myers Squibb. BusinessWire. 25 February 2016. 3 March 2016. https://web.archive.org/web/20160303172455/http://www.businesswire.com/news/home/20081211005659/en/Bristol-Myers-Squibb-Plans-Divest-U.S.-Canadian-Consumer. live.
  98. Web site: Bristol-Myers Squibb: the Pipeline. © 2015 Bristol-Myers Squibb Company. 30 May 2015. 12 May 2015. https://web.archive.org/web/20150512203055/https://www.bms.com/researchers-and-partners/in-the-pipeline.html. live.
  99. Web site: BMS Gets FDA Label Expansion for Potential Mega Blockbuster Reblozyl. Goodwin. Kate. August 29, 2023. www.biospace.com. 30 August 2023. 31 August 2023. https://web.archive.org/web/20230831055512/https://www.biospace.com/article/bms-gets-fda-label-expansion-for-potential-mega-blockbuster-reblozyl-/. live.
  100. Web site: Highlights of prescribing information. packageinserts.bms.com. 20 May 2024. 26 July 2024. https://web.archive.org/web/20240726191231/https://packageinserts.bms.com/pi/pi_reblozyl.pdf. live.
  101. Web site: A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST). classic.clinicaltrials.gov. 30 August 2023. 30 August 2023. https://web.archive.org/web/20230830125715/https://classic.clinicaltrials.gov/ct2/show/NCT02631070. live.
  102. Web site: Simonyi . Charles . Dijkgraaf . Robbert . 2016 . Report for the Academic Year 2015-2016 . live . https://web.archive.org/web/20220531231203/https://www.ias.edu/sites/default/files/documents/publications/2015-16Report.pdf . 2022-05-31 . 2022-08-02 . Institute for Advanced Study.
  103. Web site: Simonyi . Charles . Dijkgraaf . Robbert . 2015 . Report for the Academic Year 2014-2015 . live . https://web.archive.org/web/20220802184221/https://www.ias.edu/sites/default/files/documents/publications/annualreport1415_2.pdf . 2022-08-02 . 2022-08-02 . Institute for Advanced Study.
  104. Web site: Sponsors . live . https://archive.today/20220419151936/https://www.mentoringinibd.com/about-us/sponsors/ . 19 April 2022 . 2022-06-19 . Mentoring in IBD .
  105. Web site: Donor Wall . live . https://web.archive.org/web/20220619175928/https://www.nosm.ca/advancement/giving/yourimpact/donor-wall/ . 2022-06-19 . 2022-06-19 . Northern Ontario School of Medicine.
  106. Web site: Collaborations . live . https://archive.today/20220612052154/https://www.phri.ca/collaborations/ . 12 June 2022 . 2022-06-19 . . en-US .
  107. Web site: Donor Listing . live . https://archive.today/20210423095356/https://boundless.utoronto.ca/our-supporters/donor-listing/ . 23 April 2021 . 2022-06-20 . . en .
  108. Web site: 2020 . Honor Roll of Donors . live . https://web.archive.org/web/20220610164520/https://uw-s3-cdn.s3.us-west-2.amazonaws.com/wp-content/uploads/sites/83/2020/10/29094302/RTC_HonorRoll_2020.pdf . 2022-06-10 . 2022-06-20 . University of Washington
    Amazon Web Services
    .
  109. Web site: Sponsors . live . https://archive.today/20220507185453/https://www.womeninmedicinesummit.org/sponsors . 7 May 2022 . 2022-06-20 . Women in Medicine . en-US .
  110. Web site: Sponsors . live . https://archive.today/20220615052144/https://neuroscienceinnovationforum.org/sponsors/ . 15 June 2022 . 2022-06-20 . World Neuroscience Innovation Forum . en-US .
  111. Web site: Thank you to our donors . live . https://web.archive.org/web/20210629150832/https://www.camh.ca/-/media/files/camhf-2020-21-annual-report-donor-listing.pdf . 2021-06-29 . 2022-06-19 . Centre for Addiction and Mental Health.
  112. Web site: 2021 Annual Report . live . https://web.archive.org/web/20211120191604/https://thepmcf.ca/getmedia/9b96649e-83ba-490a-bacc-f961904b94c8/Annual-Report-2021_Digital.pdf . 2021-11-20 . 2022-06-20 . Princess Margaret Cancer Foundation.
  113. Web site: The 8th Princess Margaret Hospital Conference . live . https://web.archive.org/web/20220508062203/https://fdocuments.in/document/years-of-success-anna-greenberg-richard-hill-michael-jewett-david-mccready-hans.html?page=1 . 2022-05-08 . 2022-06-20 . FDocuments India . en.
  114. Web site: Our Donors . 2022-06-20 . Scarborough Health Network Foundation . en-CA . 20 June 2022 . https://web.archive.org/web/20220620072949/https://www.shnfoundation.ca/our-donors/ . live .
  115. Web site: 2020-21 SickKids Annual Report . live . https://web.archive.org/web/20220620073404/https://web.sickkidsfoundation.com/annual-report-2020/ . 2022-06-20 . 2022-06-20 . SickKids Foundation.
  116. Web site: Donor List - Cumulative . live . https://web.archive.org/web/20220516074624/https://www.sinaihealthannualreport.ca/donor-list-cumulative . 2022-05-16 . 2022-06-20 . . en.
  117. Web site: Our donors - Your Impact - Sunnybrook Foundation . live . https://web.archive.org/web/20220620153525/https://sunnybrook.ca/foundation/your-impact/our-donors-2021.html . 2022-06-20 . 2022-06-20 . . en.
  118. Web site: 2016 Annual Report Donor List . live . https://web.archive.org/web/20220510054615/https://media.nationalgeographic.org/assets/file/2016_Annual_Report_DONOR_LIST_FINAL.pdf . 2022-05-10 . 2022-06-19 . National Geographic Society.
  119. Web site: 2010-09-26 . Our Funders . dead . https://web.archive.org/web/20100926162431/http://nationalpress.org/about/our-funders/ . 2010-09-26 . 2022-06-19 . National Press Foundation
    Wayback Machine
    .
  120. Web site: Corporate Support . live . https://archive.today/20220610180740/https://www.hematology.org/about/corporate-support . 10 June 2022 . 2022-06-18 . . en .
  121. Web site: Partners . live . https://archive.today/20220514211808/https://arthritis.ca/about-us/partners . 14 May 2022 . 2022-06-18 . Arthritis Society .
  122. Web site: Sponsors . live . https://archive.today/20220515012338/https://csim.ca/conferences/virtual-annual-meeting-2021/sponsors/ . 15 May 2022 . 2022-06-19 . Canadian Society of Internal Medicine . en-US .
  123. Web site: Why sponsor the EURObservational Registry Programme . live . https://archive.today/20220615200912/https://www.escardio.org/Research/Registries-&-surveys/Sponsorship . 15 June 2022 . 2022-06-19 . .
  124. Web site: Sociedad Española de Cardiología: profesionales sanitarios y cardiólogos . live . https://web.archive.org/web/20220613161701/https://secardiologia.es/ . 2022-06-13 . 2022-06-20 . . es.
  125. Web site: 2021-12-23 . Member Listings . live . https://web.archive.org/web/20220502074149/https://www.biotech.ca/about/member-listings/ . 2022-05-02 . 2022-06-18 . . en-US.
  126. Web site: Wilson . Barry . 2000-10-05 . Biotech lobby group at heart of ethics complaint . live . https://archive.today/20220618172657/https://www.producer.com/news/biotech-lobby-group-at-heart-of-ethics-complaint/ . 18 June 2022 . 2022-06-18 . . en .
  127. Web site: Member Companies . live . https://archive.today/20211103040804/http://innovativemedicines.ca/about/member-companies/ . 3 November 2021 . 2022-06-19 . Innovative Medicines Canada . en .
  128. Web site: Companies . live . https://web.archive.org/web/20220619085601/https://www.ifpma.org/who-we-are/our-membership/full-members/companies/ . 2022-06-19 . 2022-06-19 . . en-GB.
  129. Web site: Our Members . 2022-06-19 . National Health Council . en-US . 6 April 2022 . https://web.archive.org/web/20220406081753/https://nationalhealthcouncil.org/members/?m_cat=74&m_key= . live .
  130. Web site: Members . live . https://web.archive.org/web/20211102074208/https://www.npcnow.org/about/members . 2021-11-02 . 2022-06-19 . . en.
  131. Web site: Current Members . live . https://web.archive.org/web/20210815032705/https://personalizedmedicinecoalition.org/Members/Current_Members . 2021-08-15 . 2022-06-19 . . en.
  132. Web site: PAAB : About . live . https://archive.today/20180924200521/https://www.paab.ca/about.htm . 24 September 2018 . 2022-06-19 . Pharmaceutical Advertising Advisory Board / Conseil Consultatif de Publicité Pharmaceutique . en .
  133. Web site: About . live . https://web.archive.org/web/20220615053053/https://www.phrma.org/About . 2022-06-15 . 2022-06-19 . . en.
  134. Web site: Member Organizations . live . https://archive.today/20220406092643/https://www.researchamerica.org/about-us/member-organizations . 6 April 2022 . 2022-06-20 . Research!America . en .
  135. Web site: 2019 . Annual Report 2018-2019 . live . https://web.archive.org/web/20220420013556/https://caep.ca/wp-content/uploads/2019/06/Annual-Report2019-V2.pdf . 2022-04-20 . 2022-06-18 . Canadian Association of Emergency Physicians.
  136. Web site: 2021 . Corporate Sponsors . live . https://archive.today/20220301090853/https://rheum.ca/about-us/corporate-sponsors/ . 1 March 2022 . 2022-06-18 . . en-US .
  137. Web site: Ahluwalia . Vandana . Zbib . Ahmad . 2019 . 2018-2019 Annual Report . live . https://web.archive.org/web/20220301085355/https://rheum.ca/wp-content/uploads/2019/06/cra-scr-annual-report-2019-EN-WEB.pdf . 2022-03-01 . 2022-06-18 . Canadian Rheumatology Association.
  138. Web site: 2020 . 2019-2020 Annual Report . live . https://web.archive.org/web/20220301060726/https://rheum.ca/wp-content/uploads/2020/09/ARD20_CR02_P01_cra_scr_annual_report_2020_v8b.pdf . 2022-03-01 . 2022-06-18 . Canadian Rheumatology Association.
  139. Web site: Dr. Coleman Rotstein - COVID-19 Vaccines in Oncology Patients . live . https://archive.today/20220419144918/https://careeducation.ca/dr-coleman-rotstein-covid-19-vaccines-in-oncology-patients/ . 19 April 2022 . 2022-06-19 . CARE™ Education . en-US .
  140. Web site: Our Partnerships . 2022-06-19 . Colorectal Cancer Canada . en . 16 May 2022 . https://web.archive.org/web/20220516082302/https://www.colorectalcancercanada.com/what-we-do/our-partnerships/ . dead .
  141. Web site: Members . live . https://archive.today/20220427100339/https://healthsteward.ca/members/hpsa-members/ . 27 April 2022 . 2022-06-19 . Health Products Stewardship Association . en-US .
  142. Web site: Our Partners . 2022-06-19 . Lung Health Foundation . en-US . 9 June 2022 . https://archive.today/20220609004346/https://lunghealth.ca/our-partners/ . live .
  143. Web site: How we work with the healthcare industry . 2022-06-19 . MS International Federation . en . 19 June 2022 . https://web.archive.org/web/20220619232106/https://www.msif.org/about-us/how-we-are-funded/work-healthcare-industry/ . live .
  144. Web site: Sponsors and CRO's . live . https://archive.today/20220612095635/http://www.pinnacletrials.com/sponsors/ . 12 June 2022 . 2022-06-19 . . en-US .
  145. Web site: A-Z . live . https://web.archive.org/web/20220612062914/https://www.radcliffecardiology.com/products-services/a-z . 2022-06-12 . 2022-06-20 . Radcliffe Cardiology.
  146. News: Johns Hopkins, Bristol-Myers must face $1 billion syphilis infections suit. Reuters. 4 January 2019 . 27 March 2020. 18 January 2021. https://web.archive.org/web/20210118011339/https://www.reuters.com/article/us-maryland-lawsuit-infections-idUSKCN1OY1N3. live.
  147. News: The Guatemala Experiments. Mariani. Mike. 28 May 2015. Pacific Standard. 7 January 2015. The Miller-McCune Center for Research, Media and Public Policy. 10 February 2020. https://web.archive.org/web/20200210200654/https://psmag.com/news/the-guatemala-experiments. live.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Bristol Myers Squibb".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.